Stockscreener 앱 받기
0.295
4.33%
-0.0097
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World
Ovid Therapeutics Inc [OVID] stock for 2,956 USD was sold by ALEXANDER MARGARET A. - knoxdaily.com
The OVID Stock Puzzle: Unraveling Ovid Therapeutics Inc’s Fluctuating Performance - investchronicle.com
A closer look at Ovid Therapeutics Inc (OVID) is warranted - uspostnews.com
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Libero Quotidiano.it - Libero Quotidiano
Dravet Syndrome Treatment Market Future Business - openPR.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
In Vivo’s 2025 Rising Leaders - insights.citeline.com
Ovid Therapeutics Advances Pipeline Amid Financial Progress - TipRanks
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Brain Medicine Updates: Ovid Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn - Investing.com Canada
HC Wainwright Lifts Earnings Estimates for Ovid Therapeutics - Defense World
FY2026 Earnings Forecast for OVID Issued By HC Wainwright - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Lowered to $4.00 at BTIG Research - Defense World
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Australia
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright - Investing.com
BTIG cuts Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com South Africa
BTIG cuts Ovid Therapeutics stock price target to $4 - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
West syndrome Pipeline 2025: Mechanism of Action, Route - openPR
Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst - Defense World
What is Wedbush’s Estimate for OVID FY2029 Earnings? - Defense World
William Blair Forecasts Lower Earnings for Ovid Therapeutics - Defense World
What is William Blair’s Estimate for OVID Q1 Earnings? - Defense World
Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating - MarketScreener
Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies - TipRanks
Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India
Ovid Therapeutics stock plunges to 52-week low of $0.46 By Investing.com - Investing.com South Africa
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Ovid Therapeutics Secures 2-Year Cash Runway as 3 Novel Drug Programs Progress - StockTitan
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World
Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World
2.85%
자본화:
|
볼륨(24시간):